Loading
A phase 3 trial of 9MW2821 in cervical cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06692166 by Mabwell (Shanghai) Bioscience Co., Ltd., with 420 participants planned, started 2024-09-10 and due to reach its primary completion in 2027-12-09. Interventions recorded: 9MW2821 and Chemotherapy.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Recurrent or metastatic cervical cancer, Cervical cancer and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/